References
Ahlers-Dannen KE, Spicer MM, Fisher RA
(2020). RGS Proteins as Critical Regulators of Motor Function and Their
Implications in Parkinson’s Disease. Mol Pharmacol98 (6): 730-738.
Arcuri L, Novello S, Frassineti M,
Mercatelli D, Pisano CA, Morella I, et al. (2018).
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and
selective nociceptin/orphanin FQ receptor agonists. Br J
Pharmacol 175 (5): 782-796.
Bastide MF, Meissner WG, Picconi B,
Fasano S, Fernagut PO, Feyder M, et al. (2015). Pathophysiology
of L-dopa-induced motor and non-motor complications in Parkinson’s
disease. Prog Neurobiol .
Berman DM, Wilkie TM, Gilman AG
(1996). GAIP and RGS4 are GTPase-activating proteins for the Gi
subfamily of G protein alpha subunits. Cell86 (3): 445-452.
Blazer LL, Storaska AJ, Jutkiewicz EM,
Turner EM, Calcagno M, Wade SM, et al. (2015). Selectivity and
anti-Parkinson’s potential of thiadiazolidinone RGS4 inhibitors.ACS chemical neuroscience 6 (6): 911-919.
Brugnoli A, Pisano CA, Morari M
(2020). Striatal and nigral muscarinic type 1 and type 4 receptors
modulate levodopa-induced dyskinesia and striato-nigral pathway
activation in 6-hydroxydopamine hemilesioned rats. Neurobiol Dis144: 105044.
Buzas B, Rosenberger J, Cox BM (1998).
Activity and cyclic AMP-dependent regulation of nociceptin/orphanin FQ
gene expression in primary neuronal and astrocyte cultures. J
Neurochem 71 (2): 556-563.
Cenci MA, Crossman AR (2018). Animal
models of l-dopa-induced dyskinesia in Parkinson’s disease. Mov
Disord 33 (6): 889-899.
Cenci MA, Lee CS, Bjorklund A (1998).
L-DOPA-induced dyskinesia in the rat is associated with striatal
overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.Eur J Neurosci 10 (8): 2694-2706.
Cenci MA, Lundblad M (2007). Ratings
of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of
Parkinson’s disease in rats and mice. Curr Protoc NeurosciChapter 9: Unit 9 25.
Cifelli C, Rose RA, Zhang H,
Voigtlaender-Bolz J, Bolz SS, Backx PH, et al. (2008). RGS4
regulates parasympathetic signaling and heart rate control in the
sinoatrial node. Circ Res 103 (5): 527-535.
Curtis MJ, Alexander S, Cirino G,
Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental
design and analysis and their reporting II: updated and simplified
guidance for authors and peer reviewers. Br J Pharmacol175 (7): 987-993.
Dripps IJ, Wang Q, Neubig RR, Rice
KC, Traynor JR, Jutkiewicz EM (2017). The role of regulator of G protein
signaling 4 in delta-opioid receptor-mediated behaviors.Psychopharmacology (Berl) 234 (1): 29-39.
Duty S, Jenner P (2011). Animal
models of Parkinson’s disease: a source of novel treatments and clues to
the cause of the disease. Br J Pharmacol164 (4): 1357-1391.
Ebert PJ, Campbell DB, Levitt P
(2006). Bacterial artificial chromosome transgenic analysis of dynamic
expression patterns of regulator of G-protein signaling 4 during
development. II. Subcortical regions. Neuroscience142 (4): 1163-1181.
Feng H, Sjogren B, Karaj B, Shaw V,
Gezer A, Neubig RR (2017). Movement disorder in GNAO1 encephalopathy
associated with gain-of-function mutations. Neurology89 (8): 762-770.
Ferrari F, Malfacini D, Journigan BV,
Bird MF, Trapella C, Guerrini R, et al. (2017). In vitro
pharmacological characterization of a novel unbiased NOP
receptor-selective nonpeptide agonist AT-403. Pharmacology
research & perspectives 5 (4).
Garzon J, Rodriguez-Diaz M,
Lopez-Fando A, Sanchez-Blazquez P (2001). RGS9 proteins facilitate acute
tolerance to mu-opioid effects. Eur J Neurosci13 (4): 801-811.
Geurts M, Maloteaux JM, Hermans E
(2003). Altered expression of regulators of G-protein signaling (RGS)
mRNAs in the striatum of rats undergoing dopamine depletion.Biochem Pharmacol 66 (7): 1163-1170.
Gold SJ, Ni YG, Dohlman HG, Nestler
EJ (1997). Regulators of G-protein signaling (RGS) proteins:
region-specific expression of nine subtypes in rat brain. J
Neurosci 17 (20): 8024-8037.
Gross JD, Kaski SW, Schmidt KT, Cogan
ES, Boyt KM, Wix K, et al. (2019). Role of RGS12 in the
differential regulation of kappa opioid receptor-dependent signaling and
behavior. Neuropsychopharmacology 44 (10):1728-1741.
Han MH, Renthal W, Ring RH, Rahman Z,
Psifogeorgou K, Howland D, et al. (2010). Brain region specific
actions of regulator of G protein signaling 4 oppose morphine reward and
dependence but promote analgesia. Biol Psychiatry67 (8): 761-769.
Jutkiewicz EM, Rice KC, Traynor JR,
Woods JH (2005). Separation of the convulsions and antidepressant-like
effects produced by the delta-opioid agonist SNC80 in rats.Psychopharmacology (Berl) 182 (4): 588-596.
Kimple AJ, Bosch DE, Giguere PM,
Siderovski DP (2011). Regulators of G-protein signaling and their Galpha
substrates: promises and challenges in their use as drug discovery
targets. Pharmacol Rev 63 (3): 728-749.
Ko WK, Martin-Negrier ML, Bezard E,
Crossman AR, Ravenscroft P (2014). RGS4 is involved in the generation of
abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat
model of Parkinson’s disease. Neurobiol Dis 70: 138-148.
Lerner TN, Kreitzer AC (2012). RGS4
is required for dopaminergic control of striatal LTD and susceptibility
to parkinsonian motor deficits. Neuron 73 (2):347-359.
Marti M, Mela F, Fantin M, Zucchini
S, Brown JM, Witta J, et al. (2005). Blockade of
nociceptin/orphanin FQ transmission attenuates symptoms and
neurodegeneration associated with Parkinson’s disease. J Neurosci25 (42): 9591-9601.
Marti M, Mela F, Guerrini R, Calo G,
Bianchi C, Morari M (2004). Blockade of nociceptin/orphanin FQ
transmission in rat substantia nigra reverses haloperidol-induced
akinesia and normalizes nigral glutamate release. J Neurochem91 (6): 1501-1504.
Marti M, Rodi D, Li Q, Guerrini R,
Fasano S, Morella I, et al. (2012). Nociceptin/orphanin FQ
receptor agonists attenuate L-DOPA-induced dyskinesias. J
Neurosci 32 (46): 16106-16119.
Mercatelli D, Bezard E, Eleopra R,
Zaveri NT, Morari M (2020). Managing Parkinson’s disease: moving ON with
NOP. Br J Pharmacol 177 (1): 28-47.
Neal CR, Jr., Mansour A, Reinscheid
R, Nothacker HP, Civelli O, Akil H, et al. (1999). Opioid
receptor-like (ORL1) receptor distribution in the rat central nervous
system: comparison of ORL1 receptor mRNA expression with
(125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol412 (4): 563-605.
Olianas MC, Dedoni S, Boi M, Onali P
(2008). Activation of nociceptin/orphanin FQ-NOP receptor system
inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and
dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal
striatum. J Neurochem 107 (2): 544-556.
Paolone G, Brugnoli A, Arcuri L,
Mercatelli D, Morari M (2015). Eltoprazine prevents levodopa-induced
dyskinesias by reducing striatal glutamate and direct pathway activity.Mov Disord 30 (13): 1728-1738.
Papale A, Morella IM, Indrigo MT,
Bernardi RE, Marrone L, Marchisella F, et al. (2016). Impairment
of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK
inhibitors. eLife 5 .
Pavon N, Martin AB, Mendialdua A,
Moratalla R (2006). ERK phosphorylation and FosB expression are
associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.Biol Psychiatry 59 (1): 64-74.
Paxinos G, Watson C (1986). The
rat brain in stereotaxic coordinates . 2nd edn. Academic Press: Sydney ;
Orlando.
Pisanò CA, Brugnoli A, Novello S,
Caccia C, Keywood C, Melloni E, et al. (2020). Safinamide
inhibits in vivo glutamate release in a rat model of Parkinson’s
disease. Neuropharmacology 167 .
Psifogeorgou K, Papakosta P, Russo
SJ, Neve RL, Kardassis D, Gold SJ, et al. (2007). RGS9-2 is a
negative modulator of mu-opioid receptor function. J Neurochem103 (2): 617-625.
Runne H, Regulier E, Kuhn A, Zala D,
Gokce O, Perrin V, et al. (2008). Dysregulation of gene
expression in primary neuron models of Huntington’s disease shows that
polyglutamine-related effects on the striatal transcriptome may not be
dependent on brain circuitry. J Neurosci28 (39): 9723-9731.
Sakloth F, Polizu C, Bertherat F,
Zachariou V (2020). Regulators of G protein signaling in analgesia and
addiction. Mol Pharmacol .
Santini E, Valjent E, Usiello A,
Carta M, Borgkvist A, Girault JA, et al. (2007). Critical
involvement of cAMP/DARPP-32 and extracellular signal-regulated protein
kinase signaling in L-DOPA-induced dyskinesia. J Neurosci27 (26): 6995-7005.
Schmidt ER, Morello F, Pasterkamp RJ
(2012). Dissection and culture of mouse dopaminergic and striatal
explants in three-dimensional collagen matrix assays. Journal of
visualized experiments : JoVE (61).
Schwarting RK, Huston JP (1996). The
unilateral 6-hydroxydopamine lesion model in behavioral brain research.
Analysis of functional deficits, recovery and treatments. Prog
Neurobiol 50 (2-3): 275-331.
Senese NB, Kandasamy R, Kochan KE,
Traynor JR (2020). Regulator of G-Protein Signaling (RGS) Protein
Modulation of Opioid Receptor Signaling as a Potential Target for Pain
Management. Frontiers in molecular neuroscience 13: 5.
Shen W, Plotkin JL, Francardo V, Ko
WK, Xie Z, Li Q, et al. (2015). M4 Muscarinic Receptor Signaling
Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced
Dyskinesia. Neuron 88 (4): 762-773.
Sjogren B (2017). The evolution of
regulators of G protein signalling proteins as drug targets - 20 years
in the making: IUPHAR Review 21. Br J Pharmacol174 (6): 427-437.
Stratinaki M, Varidaki A, Mitsi V,
Ghose S, Magida J, Dias C, et al. (2013). Regulator of G protein
signaling 4 [corrected] is a crucial modulator of antidepressant
drug action in depression and neuropathic pain models. Proc Natl
Acad Sci U S A 110 (20): 8254-8259.
Tesmer JJ, Berman DM, Gilman AG,
Sprang SR (1997). Structure of RGS4 bound to AlF4–activated G(i
alpha1): stabilization of the transition state for GTP hydrolysis.Cell 89 (2): 251-261.
Toll L, Bruchas MR, Calo G, Cox BM,
Zaveri NT (2016). Nociceptin/Orphanin FQ Receptor Structure, Signaling,
Ligands, Functions, and Interactions with Opioid Systems.Pharmacol Rev 68 (2): 419-457.
Traynor J (2012). mu-Opioid receptors
and regulators of G protein signaling (RGS) proteins: from a symposium
on new concepts in mu-opioid pharmacology. Drug Alcohol Depend121 (3): 173-180.
Traynor JR, Neubig RR (2005).
Regulators of G protein signaling & drugs of abuse. Mol Interv5 (1): 30-41.
Turner EM, Blazer LL, Neubig RR,
Husbands SM (2012). Small Molecule Inhibitors of Regulator of G Protein
Signalling (RGS) Proteins. ACS medicinal chemistry letters3 (2): 146-150.
Viaro R, Sanchez-Pernaute R, Marti M,
Trapella C, Isacson O, Morari M (2008). Nociceptin/orphanin FQ receptor
blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis30 (3): 430-438.
Xie GX, Yanagisawa Y, Ito E, Maruyama
K, Han X, Kim KJ, et al. (2005). N-terminally truncated variant
of the mouse GAIP/RGS19 lacks selectivity of full-length GAIP/RGS19
protein in regulating ORL1 receptor signaling. J Mol Biol353 (5): 1081-1092.
Zachariou V, Georgescu D, Sanchez N,
Rahman Z, DiLeone R, Berton O, et al. (2003). Essential role for
RGS9 in opiate action. Proc Natl Acad Sci U S A100 (23): 13656-13661.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8